Summary
Mixed alignment: many claims are supported by the label (CNS depression, respiratory risk, opioid interactions, monitoring, and non-drug alternatives), but several claims are off-label or not explicitly supported by the provided labeling excerpts. Critical label elements such as boxed warnings, explicit pregnancy/pediatric considerations, and pediatric safety are not directly mapped to the claims.
Category Scores
MonitoringRecommendations
65
Accurate Statements
The combination can lead to profound CNS depression and respiratory depression, particularly with higher doses or concomitant use of other CNS depressants (e.g., alcohol, opioids).
5.1, 5.9, 7.1, 10
Naloxone won't reverse benzodiazepines or other sedatives; it reverses opioids if involved.
17
Seek emergency help if severe overdose or sedation occurs.
10, 17
Driving or operating machinery is dangerous with CNS depressants and concomitant alcohol use should be avoided.
5.4, 17
Unsupported Statements
Dosing example: Xanax 0.25-0.5 mg plus trazodone 50 mg at bedtime.
Off-label dosing example not specified in the provided label excerpts; no explicit combination dosing example is present in the supplied label sections.
FDA interaction checker flags this combination as a major interaction.
Label excerpt provided (7.1) supports major interactions generally, but the explicit phrase 'FDA interaction checker flags this combination as a major interaction' is not a direct quote from the supplied label text.
Contradictions
Important Omissions
Boxed warnings specific to benzodiazepine use with severe CNS depressants or opioids (and their explicit statements) are not directly mapped to a labeled boxed warning in the provided excerpts.
Importance:
Moderate
Pregnancy risk labeling (teratogenicity, neonatal withdrawal, birth outcomes) for alprazolam and trazodone, including any risk classifications, is not explicitly cited in the provided label excerpts.
Importance:
High
Pediatric safety and dosing considerations for combined use (age-specific risks) are not explicitly cited in the provided label excerpts.
Importance:
Moderate
Explicit guidance regarding sleep apnea or significant respiratory comorbidity in the context of alprazolam plus trazodone is not directly mapped beyond general respiratory risk.
Importance:
Moderate
Safety Assessment
Potential Patient Risk:
Low
Label supports risk with CNS depressants and respiratory suppression; risk is primarily within known benzodiazepine–CNS depressant interactions and visitor monitoring rather than an unexpected new hazard.
Regulatory Assessment
| On Label |
Yes |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
Low |
Recommendation
Mostly Aligned
Primary Issue
Suggested Improvement